Kidney Cancer

Videos

An analysis revealed that as a third- or fourth-line treatment for RCC, tivozanib significantly increased Q-TWiST compared with sorafenib, primarily through an increase in TWiST.

Michael Szarek, PhD, on the Outcomes of a Q-TWiST Analysis From the Phase 3 TIVO-3 Study

Articles

“These updated results from the phase 2 MERECA trial underscore the positive impact on overall survival that ilixadencel may achieve for [patients with kidney cancer],” said Sven Rohmann, MD, PhD.

Phase 2 MERECA Trial Continues to Show Promise for Ilixadencel-Sunitinib Combination for mRCC

In the phase 3 CheckMate 9ER trial, investigators found that nivolumab plus cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously untreated advanced renal cell carcinoma.

Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ER

In the CheckMate 9ER trial, investigators compared combination treatment with nivolumab and cabozantinib versus sunitinib in patients with previously treated advanced renal cell carcinoma.

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC

Follow-up data published in the European Association of Urology did not find a significant improvement in overall survival for patients with locally advanced renal cell carcinoma undergoing adjuvant pazopanib treatment.

Adjuvant Pazopanib Does Not Improve Overall Survival for Patients With Locally Advanced RCC

A Q-TWiST analysis evaluated the use of tivozanib versus sorafenib among patients with advanced renal cell carcinoma included in the phase 3 TIVO-3 study.

Michael Szarek, PhD, on the Rationale Behind Conducting a Q-TWiST Analysis of the Phase 3 TIVO-3 Study

Investigators compared lenvatinib plus either pembrolizumab or everolimus versus sunitinib in patients with advanced renal cell carcinoma in the CLEAR trial.

Robert J. Motzer, MD, on Next Steps for the Phase 3 CLEAR Trial for Advanced RCC

An expert discusses how new data from the phase 3 CheckMate 9ER trial impact therapy choice in previously untreated advanced renal cell carcinoma.

Toni Choueiri, MD, on How New Data Impact the Standard of Care for RCC

The CLEAR trial compared treatment with lenvatinib plus either pembrolizumab or everolimus versus sunitinib in patients with advanced renal cell carcinoma.

Robert J. Motzer, MD, on the Results of the Phase 3 CLEAR Trial for Advanced RCC

In the CLEAR study, investigators compared lenvatinib plus either pembrolizumab or everolimus versus sunitinib in patients with advanced renal cell carcinoma.

Renal Cell Carcinoma | Topics